Madurai News

The Schizophrenia Market Size was USD 8,664.6 million in 2021

 Breaking News
  • No posts were found

The Schizophrenia Market Size was USD 8,664.6 million in 2021

November 21
10:17 2022
The Schizophrenia Market Size was USD 8,664.6 million in 2021

The Schizophrenia Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development.

 

The Schizophrenia market research report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Schizophrenia market size. The Schizophrenia market report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Key takeaways from the Schizophrenia Market Research Report

  • According to the DelveInsight, in the year 2021, the total prevalent cases of Schizophrenia were 2.97 million in the United States which are expected to grow during the study period, i.e., 2019–2032.
  • The highest number of total prevalent cases of Schizophrenia among the EU5 countries was observed in Germany with 0.61 million cases in 2021 which are expected to grow during the study period, i.e., 2019–2032.
  • In the year 2021, the total prevalent cases of Schizophrenia were 1.08 million cases in Japan which are expected to grow during the study period, i.e., 2019–2032.
  • Schizophrenia Market Companies are working include Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
  • Schizophrenia Pipeline Therapies includes Digital therapeutics app CT-155, Cariprazine, Aripiprazole IM Depot, CTP-692, Brexpiprazole, Aripiprazole, Luvadaxistat, Luvadaxistat, and others.

 

Discover more about therapies set to grab major Schizophrenia market research report @ Schizophrenia Market Size

 

Schizophrenia Overview

Schizophrenia is not a split or multiple personalities. Besides, it is not caused by childhood experiences, poor parenting, or lack of willpower, nor the symptoms are identical in each patient. In addition, the vast majority of people with schizophrenia are not violent and do not pose a danger to others. In some people, schizophrenia appears suddenly and without warning. But for most, it comes on slowly, with subtle warning signs and a gradual decline in functioning long before the first severe episode. Often, friends or family members will know early on that something is wrong without knowing exactly what.

 

Schizophrenia Epidemiology Segmentation in the 7MM

  • Total Schizophrenia Prevalent Cases
  • Total Schizophrenia Diagnosed Cases
  • Schizophrenia Gender-specific Cases
  • Schizophrenia Severity-specific Cases
  • Schizophrenia Age-specific Treated Cases
  • Total Schizophrenia Treated Cases

 

Download the report to understand which factors are driving Schizophrenia market trends @ Schizophrenia Market Outlook

 

Schizophrenia Treatment Market

The treatment options for schizophrenia include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. New research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents to improve schizophrenia management and address the above-mentioned gaps.

 

Schizophrenia Market Outlook

With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and prevention of relapsed cases. Schizophrenia requires lifelong treatment, even when symptoms have subsided. Treatment with medications and psychosocial therapy can help manage the condition. In some cases, hospitalization may be needed. Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics are the first choice among psychotropic agents used to treat schizophrenia. For some patient groups, treatment strategies include a combination of neuroleptics and antiepileptics. Second-generation antipsychotic (SGAs) medications are generally preferred because they pose a lower risk of serious side effects than first-generation antipsychotics (FGAs). The FGAs have frequent and potentially significant neurological side effects, including the possibility of developing a movement disorder (tardive dyskinesia) that may or may not be reversible.

 

Learn more about Schizophrenia therapies in clinical trials @ Schizophrenia Market Share

 

Scope of the Schizophrenia Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Schizophrenia Companies- Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others
  • Schizophrenia Pipeline therapies- Digital therapeutics app CT-155, Cariprazine, Aripiprazole IM Depot, CTP-692, Brexpiprazole, Aripiprazole, Luvadaxistat, Luvadaxistat, and others
  • Schizophrenia Therapeutic Assessment: Pancreatic Cancer current marketed and emerging therapies
  • Schizophrenia Market Dynamics:  Schizophrenia Market Drivers and Barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Schizophrenia Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Schizophrenia Report Introduction

3. Schizophrenia Market Overview at a Glance

4. Executive Summary of Schizophrenia

5. Schizophrenia Epidemiology and Market Methodology

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Patient Journey

9. Key Endpoints in Schizophrenia Clinical Trials

10. Schizophrenia Marketed Therapies

11. Schizophrenia Emerging Therapies

12. Conjoint Analysis

13. Schizophrenia: 7 Major Market Analysis

14. Schizophrenia Market Access and Reimbursement

15. KOL Views

16. SWOT Analysis

17. Schizophrenia Unmet Needs

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Got Queries? Consult with our Business Expert @ Schizophrenia Emerging Therapies

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/